ZD1839 (Iressa™) in non-small-cell lung cancer

R. S. Herbst; F. R. Khuri; F. V. Fossella; B. S. Glisson; M. S. Kies; K. M. Pisters; J. R. Riddle; K. A. Terry; J. Soo Lee

doi:10.3816/CLC.2001.n.014

ZD1839 (Iressa™) in non-small-cell lung cancer

R. S. Herbst, F. R. Khuri, F. V. Fossella, B. S. Glisson, M. S. Kies, K. M. Pisters, J. R. Riddle, K. A. Terry, J. Soo Lee

Thoracic Head & Neck Medical Oncology

Research output: Contribution to journal › Review article › peer-review

17 Scopus citations

Abstract

The epidermal growth factor receptor (EGFR) signaling pathway plays an important role in a number of processes that are key to tumor progression, including cell proliferation, angiogenesis, metastatic spread, and inhibition of apoptosis. EGFR is expressed or overexpressed in non-small-cell lung cancer (NSCLC), and EGFR-mediated growth has been associated with advanced disease and poor prognosis in NSCLC patients. ZD1839 (Iressa^TM) is an orally active, selective EGFR-tyrosine kinase inhibitor that blocks EGFR signal transduction. In preclinical studies using NSCLC cell lines, ZD1839 has been shown to inhibit tumor cell growth. In addition, ZD1839, as monotherapy and in combination with commonly used cytotoxic agents, has produced growth delay in NSCLC human xenografts. Preliminary results from phase I trials in patients with advanced disease have shown that ZD1839 has excellent bioavailability, an acceptable tolerability profile, and promising clinical activity in patients with a variety of tumor types, particularly in NSCLC. ZD1839 is currently in phase III clinical development for the treatment of advanced NSCLC.

Original language	English (US)
Pages (from-to)	27-32
Number of pages	6
Journal	Clinical Lung Cancer
Volume	3
Issue number	1
DOIs	https://doi.org/10.3816/CLC.2001.n.014
State	Published - 2001

Keywords

Biologic therapy
Combination chemotherapy
Epidermal growth factor receptor
Orally active chemotherapy
Synergy
Targeted therapy
Tyrosine kinase inhibitor

ASJC Scopus subject areas

Oncology
Pulmonary and Respiratory Medicine
Cancer Research

Access to Document

10.3816/CLC.2001.n.014

Cite this

@article{83854bcc1cd343148358f03615faee54,

title = "ZD1839 (Iressa{\texttrademark}) in non-small-cell lung cancer",

abstract = "The epidermal growth factor receptor (EGFR) signaling pathway plays an important role in a number of processes that are key to tumor progression, including cell proliferation, angiogenesis, metastatic spread, and inhibition of apoptosis. EGFR is expressed or overexpressed in non-small-cell lung cancer (NSCLC), and EGFR-mediated growth has been associated with advanced disease and poor prognosis in NSCLC patients. ZD1839 (IressaTM) is an orally active, selective EGFR-tyrosine kinase inhibitor that blocks EGFR signal transduction. In preclinical studies using NSCLC cell lines, ZD1839 has been shown to inhibit tumor cell growth. In addition, ZD1839, as monotherapy and in combination with commonly used cytotoxic agents, has produced growth delay in NSCLC human xenografts. Preliminary results from phase I trials in patients with advanced disease have shown that ZD1839 has excellent bioavailability, an acceptable tolerability profile, and promising clinical activity in patients with a variety of tumor types, particularly in NSCLC. ZD1839 is currently in phase III clinical development for the treatment of advanced NSCLC.",

keywords = "Biologic therapy, Combination chemotherapy, Epidermal growth factor receptor, Orally active chemotherapy, Synergy, Targeted therapy, Tyrosine kinase inhibitor",

author = "Herbst, {R. S.} and Khuri, {F. R.} and Fossella, {F. V.} and Glisson, {B. S.} and Kies, {M. S.} and Pisters, {K. M.} and Riddle, {J. R.} and Terry, {K. A.} and {Soo Lee}, J.",

year = "2001",

doi = "10.3816/CLC.2001.n.014",

language = "English (US)",

volume = "3",

pages = "27--32",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier",

number = "1",

}

TY - JOUR

T1 - ZD1839 (Iressa™) in non-small-cell lung cancer

AU - Herbst, R. S.

AU - Khuri, F. R.

AU - Fossella, F. V.

AU - Glisson, B. S.

AU - Kies, M. S.

AU - Pisters, K. M.

AU - Riddle, J. R.

AU - Terry, K. A.

AU - Soo Lee, J.

PY - 2001

Y1 - 2001

N2 - The epidermal growth factor receptor (EGFR) signaling pathway plays an important role in a number of processes that are key to tumor progression, including cell proliferation, angiogenesis, metastatic spread, and inhibition of apoptosis. EGFR is expressed or overexpressed in non-small-cell lung cancer (NSCLC), and EGFR-mediated growth has been associated with advanced disease and poor prognosis in NSCLC patients. ZD1839 (IressaTM) is an orally active, selective EGFR-tyrosine kinase inhibitor that blocks EGFR signal transduction. In preclinical studies using NSCLC cell lines, ZD1839 has been shown to inhibit tumor cell growth. In addition, ZD1839, as monotherapy and in combination with commonly used cytotoxic agents, has produced growth delay in NSCLC human xenografts. Preliminary results from phase I trials in patients with advanced disease have shown that ZD1839 has excellent bioavailability, an acceptable tolerability profile, and promising clinical activity in patients with a variety of tumor types, particularly in NSCLC. ZD1839 is currently in phase III clinical development for the treatment of advanced NSCLC.

AB - The epidermal growth factor receptor (EGFR) signaling pathway plays an important role in a number of processes that are key to tumor progression, including cell proliferation, angiogenesis, metastatic spread, and inhibition of apoptosis. EGFR is expressed or overexpressed in non-small-cell lung cancer (NSCLC), and EGFR-mediated growth has been associated with advanced disease and poor prognosis in NSCLC patients. ZD1839 (IressaTM) is an orally active, selective EGFR-tyrosine kinase inhibitor that blocks EGFR signal transduction. In preclinical studies using NSCLC cell lines, ZD1839 has been shown to inhibit tumor cell growth. In addition, ZD1839, as monotherapy and in combination with commonly used cytotoxic agents, has produced growth delay in NSCLC human xenografts. Preliminary results from phase I trials in patients with advanced disease have shown that ZD1839 has excellent bioavailability, an acceptable tolerability profile, and promising clinical activity in patients with a variety of tumor types, particularly in NSCLC. ZD1839 is currently in phase III clinical development for the treatment of advanced NSCLC.

KW - Biologic therapy

KW - Combination chemotherapy

KW - Epidermal growth factor receptor

KW - Orally active chemotherapy

KW - Synergy

KW - Targeted therapy

KW - Tyrosine kinase inhibitor

UR - http://www.scopus.com/inward/record.url?scp=0034789215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034789215&partnerID=8YFLogxK

U2 - 10.3816/CLC.2001.n.014

DO - 10.3816/CLC.2001.n.014

M3 - Review article

C2 - 14656386

AN - SCOPUS:0034789215

SN - 1525-7304

VL - 3

SP - 27

EP - 32

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

IS - 1

ER -

ZD1839 (Iressa™) in non-small-cell lung cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this